Pharmesis International Ltd. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
For the nine months, revenue was RMB 46.064 million against RMB 45.718 million last year. Loss from operations was RMB 1.055 million against loss from operations of RMB 3.723 million last year. Profit before tax was RMB 1.511 million against loss before tax of RMB 1.704 million last year. Profit attributable to equity holders of the company was RMB 0.7 million against loss attributable to equity holders of the company of RMB 0.699 million last year. Net cash flows from operating activities were RMB 6.445 million against RMB 4.107 million last year. Acquisition of property, plant and equipment was RMB 1.423 million against RMB 0.294 million last year. Earnings per share on fully diluted basis were 3.50 cents against loss per share on fully diluted basis of 3.50 cents last year.